Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 78462, held by Aurobindo Pharma. Topiramate.
As of Nov 15, 2026, ANDA 78462 (Topiramate), held by Aurobindo Pharma, was first approved by FDA on Mar 27, 2009, with 25 approved supplements and 0 published complete response letters.
Topiramate tablets are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2009 | Original application | Approved |
| Topiramate25MG · tablet;oral | Topiramate | Rx |
| Topiramate50MG · tablet;oral | Topiramate | Rx |
| Topiramate100MG · tablet;oral | Topiramate | Rx |
| Topiramate200MG · tablet;oral | Topiramate | Rx |
| Oct 14, 2026 | Supplement 38Labeling · Standard review | Approved | None posted |
| Oct 7, 2025 | Supplement 36Labeling · Standard review | Approved | None posted |
| Jan 4, 2024 | Supplement 33Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 32Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 30Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 28Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 27Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 21Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 20Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jan 10, 2022 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 14Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 20, 2014 | Supplement 7Labeling | Approved | None posted |
| Jul 7, 2011 | Supplement 5Labeling | Approved | None posted |
| Nov 4, 2010 | Supplement 3Labeling | Approved | None posted |
| Feb 23, 2010 | Supplement 2Labeling | Approved | None posted |
| Feb 23, 2010 | Supplement 1Labeling | Approved | None posted |
| Mar 27, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters